Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 18/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.98 |
| ▸ | MEN1 | O00255 | 4/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.98 |
| ▸ | GLA | P06280 | 3/20 | 0.98 |
| ▸ | TP53 | P04637 | 2/20 | 0.98 |
| ▸ | HPGD | P15428 | 2/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | HBB | P68871 | 2/20 | 0.98 |
| ▸ | STAT6 | P42226 | 1/20 | 0.98 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.98 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.98 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.98 |
| ▸ | GMNN | O75496 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | HNRNPA1 | P09651 | 1/20 | 0.98 |
| ▸ | GAA | P10253 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Camptothecin SCHEMBL4304557 | 0.99 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL2298909 | 0.99 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL28057307 | 0.99 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL29351099 | 0.99 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL788063 | 0.99 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL6038 | 0.99 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL29360250 | 0.99 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL29369924 | 0.99 | TOP1 (1.00) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL3117386 | 0.98 | TOP1 (0.98) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Camptothecin SCHEMBL17112859 | 0.98 | TOP1 (0.98) | TOP1ALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 380 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313900-A1 | COMPOSITIONS AND THERAPEUTIC AGENTS FOR MODULATING INFLAMMATORY RESPONSES ON BOTH TUMOR AND IMMUNE CELLS | THE METHODIST HOSPITAL | 2025-10-09 | — | — | US | claimed |
| WO-2023240291-A2 | COMPOSITIONS AND THERAPEUTIC AGENTS FOR MODULATING INFLAMMATORY RESPONSES ON BOTH TUMOR AND IMMUNE CELLS | THE METHODIST HOSPITAL SYSTEM (US) | 2023-12-14 | — | — | WO | claimed |
| CN-104839223-B | A kind of plant source compound insecticide and application thereof | 浙江大学 | 2018-01-05 | — | — | CN | claimed |
| CN-104839223-A | Botanical compound insecticide and applications thereof | UNIV ZHEJIANG | 2015-08-19 | — | — | CN | claimed |
| US-8945629-B2 | Nanoparticles for cytoplasmic drug delivery to cancer cells | UNIVERSITY OF WYOMING (US) | 2015-02-03 | — | — | US | claimed |
| US-8110544-B2 | RasGAP derived peptide for selectively killing cancer cells | UNIVERSITE DE LAUSANNE (CH) | 2012-02-07 | — | — | US | claimed |
| US-20100273823-A1 | Pesticide Composition Solution and Preparation Method Thereof | ZHEJIANG FORESTRY COLLEGE (CN) | 2010-10-28 | — | — | US | claimed |
| US-20100203149-A1 | Nanoparticles for Cytoplasmic Drug Delivery to Cancer Cells | UNIVERSITY OF WYOMING (US) | 2010-08-12 | — | — | US | claimed |
| EP-1641820-B1 | RASGAP DERIVED PEPTIDE FOR SELECTIVELY KILLING CANCER CELLS | UNIV LAUSANNE (CH) | 2008-05-28 | — | — | EP | claimed |
| US-20070190102-A1 | Method of preparing hydroxyapatite based drug delivery implant for infection and cancer treatment | LUO PING | 2007-08-16 | — | — | US | claimed |
| WO-2007001356-A2 | NANOPARTICLES FOR CYTOPLASMIC DRUG DELIVERY TO CANCER CELLS | UNIVERSITY OF WYOMING (US) | 2007-01-04 | — | — | WO | claimed |
| US-20060234929-A1 | Rasgap derived peptide for selectively killing cancer cells | UNIVERSITE DE LAUSANNE (CH) | 2006-10-19 | — | — | US | claimed |
| US-12628858-B2 | Therapy for colorectal and small intestine cancers | CORNELL UNIVERSITY (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250313900-A1 | COMPOSITIONS AND THERAPEUTIC AGENTS FOR MODULATING INFLAMMATORY RESPONSES ON BOTH TUMOR AND IMMUNE CELLS | THE METHODIST HOSPITAL | 2025-10-09 | — | — | US | disclosed |
| US-20250049940-A1 | Combined Use of Anti-TROP-2 Antibody-drug Conjugate and other Therapeutic Agents | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-02-13 | — | — | US | disclosed |
| US-12180551-B2 | Method of using biomarkers and clinical variables for predicting chemotherapy benefit | MYRIAD INTERNATIONAL GMBH (DE) | 2024-12-31 | — | — | US | disclosed |
| CN-1042151-A | The preparation method of Camptothecin arginic acid salt preparation | SHENYANG CITY MATERIA MEDICA C (CN) | 1990-05-16 | — | — | CN | disclosed |
| CN-1042151-A | The preparation method of Camptothecin arginic acid salt preparation | SHENYANG CITY MATERIA MEDICA C (CN) | 1990-05-16 | — | — | CN | disclosed |
| US-4914205-A | Camptothecin derivatives | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1990-04-03 | — | — | US | disclosed |
| EP-0296612-A1 | Camptothecin derivatives and process for preparing same | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1988-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273823-A1 | Pesticide Composition Solution and Preparation Method Thereof | HCN1, KCNH3, KCNH2 | TOP1 3536/4885ALDH1A1 1800/4885MEN1 2519/4885 |
| US-20250313900-A1 | COMPOSITIONS AND THERAPEUTIC AGENTS FOR MODULATING INFLAMMATORY RESPONSES ON BOTH TUMOR AND IMMUNE CELLS | MIF, CCL2, MPEG1 | TOP1 3826/4885ALDH1A1 4355/4885MEN1 4240/4885 |
| US-20250049940-A1 | Combined Use of Anti-TROP-2 Antibody-drug Conjugate and other Therapeutic Agents | PDCD1LG2, TPM3, CD274 | TOP1 72/4885ALDH1A1 809/4885MEN1 2018/4885 |
| US-12628858-B2 | Therapy for colorectal and small intestine cancers | FABP2, PKN2, APC | TOP1 4517/4885ALDH1A1 4014/4885MEN1 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.